These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

586 related articles for article (PubMed ID: 27302362)

  • 21. Low dose EGCG treatment beginning in adolescence does not improve cognitive impairment in a Down syndrome mouse model.
    Stringer M; Abeysekera I; Dria KJ; Roper RJ; Goodlett CR
    Pharmacol Biochem Behav; 2015 Nov; 138():70-9. PubMed ID: 26363314
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABA
    Goeldner C; Kishnani PS; Skotko BG; Casero JL; Hipp JF; Derks M; Hernandez MC; Khwaja O; Lennon-Chrimes S; Noeldeke J; Pellicer S; Squassante L; Visootsak J; Wandel C; Fontoura P; d'Ardhuy XL;
    J Neurodev Disord; 2022 Feb; 14(1):10. PubMed ID: 35123401
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Short- and long-term effects of neonatal pharmacotherapy with epigallocatechin-3-gallate on hippocampal development in the Ts65Dn mouse model of Down syndrome.
    Stagni F; Giacomini A; Emili M; Trazzi S; Guidi S; Sassi M; Ciani E; Rimondini R; Bartesaghi R
    Neuroscience; 2016 Oct; 333():277-301. PubMed ID: 27457036
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship between speech, oromotor, language and cognitive abilities in children with Down's syndrome.
    Cleland J; Wood S; Hardcastle W; Wishart J; Timmins C
    Int J Lang Commun Disord; 2010; 45(1):83-95. PubMed ID: 19821789
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.
    Lannfelt L; Blennow K; Zetterberg H; Batsman S; Ames D; Harrison J; Masters CL; Targum S; Bush AI; Murdoch R; Wilson J; Ritchie CW;
    Lancet Neurol; 2008 Sep; 7(9):779-86. PubMed ID: 18672400
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study.
    Peyro Saint Paul L; Creveuil C; Heinzlef O; De Seze J; Vermersch P; Castelnovo G; Cabre P; Debouverie M; Brochet B; Dupuy B; Lebiez P; Sartori É; Clavelou P; Brassat D; Lebrun-Frenay C; Daplaud D; Pelletier J; Coman I; Hautecoeur P; Tourbah A; Defer G
    J Neurol Sci; 2016 Apr; 363():69-76. PubMed ID: 27000224
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tasimelteon for non-24-hour sleep-wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials.
    Lockley SW; Dressman MA; Licamele L; Xiao C; Fisher DM; Flynn-Evans EE; Hull JT; Torres R; Lavedan C; Polymeropoulos MH
    Lancet; 2015 Oct; 386(10005):1754-64. PubMed ID: 26466871
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term results of treatment with bosentan in adult Eisenmenger's syndrome patients with Down's syndrome related to congenital heart disease.
    Crepaz R; Romeo C; Montanaro D; De Santis S
    BMC Cardiovasc Disord; 2013 Sep; 13():74. PubMed ID: 24047157
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of epigallocatechin gallate on the body composition and lipid profile of down syndrome individuals: Implications for clinical management.
    Xicota L; Rodríguez J; Langohr K; Fitó M; Dierssen M; de la Torre R;
    Clin Nutr; 2020 Apr; 39(4):1292-1300. PubMed ID: 31229326
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial.
    Nguyen QD; Merrill PT; Jaffe GJ; Dick AD; Kurup SK; Sheppard J; Schlaen A; Pavesio C; Cimino L; Van Calster J; Camez AA; Kwatra NV; Song AP; Kron M; Tari S; Brézin AP
    Lancet; 2016 Sep; 388(10050):1183-92. PubMed ID: 27542302
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapy for pulmonary arterial hypertension due to congenital heart disease and Down's syndrome.
    D'Alto M; Romeo E; Argiento P; D'Andrea A; Sarubbi B; Correra A; Scognamiglio G; Papa S; Bossone E; Calabrò R; Vizza CD; Russo MG
    Int J Cardiol; 2013 Apr; 164(3):323-6. PubMed ID: 21802156
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial.
    Poewe W; Seppi K; Fitzer-Attas CJ; Wenning GK; Gilman S; Low PA; Giladi N; Barone P; Sampaio C; Eyal E; Rascol O;
    Lancet Neurol; 2015 Feb; 14(2):145-52. PubMed ID: 25498732
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.
    Bigal ME; Dodick DW; Rapoport AM; Silberstein SD; Ma Y; Yang R; Loupe PS; Burstein R; Newman LC; Lipton RB
    Lancet Neurol; 2015 Nov; 14(11):1081-90. PubMed ID: 26432182
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Green tea EGCG plus fish oil omega-3 dietary supplements rescue mitochondrial dysfunctions and are safe in a Down's syndrome child.
    Vacca RA; Valenti D
    Clin Nutr; 2015 Aug; 34(4):783-4. PubMed ID: 25962746
    [No Abstract]   [Full Text] [Related]  

  • 35. Safety and efficacy of rivastigmine in children with Down syndrome: A double blind placebo controlled trial.
    Spiridigliozzi GA; Hart SJ; Heller JH; Schneider HE; Baker JA; Weadon C; Capone GT; Kishnani PS
    Am J Med Genet A; 2016 Jun; 170(6):1545-55. PubMed ID: 27061338
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of early thyroxine treatment on development and growth at age 10.7 years: follow-up of a randomized placebo-controlled trial in children with Down's syndrome.
    Marchal JP; Maurice-Stam H; Ikelaar NA; Klouwer FC; Verhorstert KW; Witteveen ME; Houtzager BA; Grootenhuis MA; van Trotsenburg AS
    J Clin Endocrinol Metab; 2014 Dec; 99(12):E2722-9. PubMed ID: 25243574
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 'Benifuuki' green tea containing o-methylated catechin reduces symptoms of Japanese cedar pollinosis: a randomized, double-blind, placebo-controlled trial.
    Masuda S; Maeda-Yamamoto M; Usui S; Fujisawa T
    Allergol Int; 2014 Jun; 63(2):211-7. PubMed ID: 24561771
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.
    Chupp GL; Bradford ES; Albers FC; Bratton DJ; Wang-Jairaj J; Nelsen LM; Trevor JL; Magnan A; Ten Brinke A
    Lancet Respir Med; 2017 May; 5(5):390-400. PubMed ID: 28395936
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial.
    Cudkowicz ME; van den Berg LH; Shefner JM; Mitsumoto H; Mora JS; Ludolph A; Hardiman O; Bozik ME; Ingersoll EW; Archibald D; Meyers AL; Dong Y; Farwell WR; Kerr DA;
    Lancet Neurol; 2013 Nov; 12(11):1059-67. PubMed ID: 24067398
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Zhu FC; Wurie AH; Hou LH; Liang Q; Li YH; Russell JB; Wu SP; Li JX; Hu YM; Guo Q; Xu WB; Wurie AR; Wang WJ; Zhang Z; Yin WJ; Ghazzawi M; Zhang X; Duan L; Wang JZ; Chen W
    Lancet; 2017 Feb; 389(10069):621-628. PubMed ID: 28017399
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.